Molecular Quality Controls Market: Market Size & Forecast 2026

Molecular quality controls are standardized reference materials designed to verify the performance of molecular diagnostic instruments and assays, ensuring test results are accurate, reproducible, and clinically reliable. The market spans control types including whole-blood, serum, plasma, and synthetic RNA/DNA controls, supporting applications across infectious disease testing, oncology, genetic disease screening, and prenatal diagnostics. North America currently dominates the global market, supported by advanced healthcare infrastructure, stringent regulatory oversight, and early adoption of molecular testing technologies in clinical laboratories.

• •Market valued at approximately $228-234 million in 2025, with a 2025 baseline of ~$233 million
• •Expected to reach roughly $420 million by 2034 under longer-term projections, reflecting steady multi-year expansion
• •Product categories include whole-blood controls, plasma/serum controls, synthetic controls, and pathogen-specific controls

The increasing adoption of molecular diagnostics in clinical and research settings is a central growth catalyst, as laboratories require certified controls to comply with regulatory standards such as CLIA, CAP, and FDA requirements. The rising global burden of infectious diseases, including HIV, hepatitis, and respiratory pathogens, along with growing demand for oncology companion diagnostics, has substantially expanded the volume of molecular tests requiring quality control verification. Additionally, advances in next-generation sequencing and the shift toward precision medicine continue to create new demand for molecular quality control products across a widening array of test platforms and methodologies.

• •Growing volume of molecular diagnostic testing in hospitals, reference labs, and research institutions globally
• •Stringent regulatory mandates requiring continuous assay validation and quality assurance
• •Expanding oncology companion diagnostic pipelines and NGS-based test adoption

By product type, the market is typically segmented into whole-blood-based controls, serum/plasma controls, synthetic nucleic acid controls, and pathogen-specific controls, with synthetic controls gaining traction due to their stability and consistency. By application, infectious disease testing represents the largest segment, followed by oncology and genetic disease diagnostics, with companion diagnostics emerging as a fast-growing sub-segment. Geographically, North America holds the largest share, with Europe and Asia-Pacific as the next most significant regions, the latter propelled by increasing healthcare expenditure and expanding diagnostic laboratory capacity in countries such as China and India.

• •Infectious disease diagnostics is the dominant application segment, with oncology and genetic disease testing also representing major demand areas
• •North America leads globally, with Europe and Asia-Pacific as the second and third largest regional markets
• •Synthetic molecular controls are an increasingly important product category due to stability and customization advantages

What are the recent trends and outlook?

The market is moving toward more comprehensive and digitalized quality control solutions, including controls designed for next-generation sequencing workflows and multiplex PCR panels that reflect the increasing complexity of modern molecular diagnostics. The growing emphasis on laboratory accreditation and standardized quality management systems continues to drive consistent demand for certified molecular controls across all geographic markets. Over the medium term, continued expansion of molecular testing into emerging markets, combined with ongoing regulatory tightening and the proliferation of novel molecular platforms, positions the market for sustained growth through the 2030s.

• •NGS-specific quality controls and digital quality management tools represent emerging product innovation areas
• •Companion diagnostics and liquid biopsy molecular tests are creating new quality control demand
• •Emerging-market expansion in Asia-Pacific and Latin America is expected to become an increasingly important growth vector